Health Care • Biotechnology: Pharmaceutical Preparations
$95.51 ▼ -1.05
(-1.09%)
MKT CAP: $10.08B • VOL: 752.1K
52W L $21 52W H $110
SYRE // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $586.8M | $584.0M | $886.0K |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $0 | $0 | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$209.6M | -$208.6M | -$242.3M |
| Operating Margin % | — | — | -27348.0% |
| Net Income (GAAP) | -$155.2M | -$208.0M | -$338.8M |
| EBITDA (Normalized) | -$209.6M | -$208.6M | -$242.3M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$169.3M | -$157.4M | -$99.9M |
| Capital Expenditures (CapEx) | $0 | $0 | $39.9K |
| Free Cash Flow (FCF) | -$169.3M | -$157.4M | -$99.9M |
| FCF Margin % | — | — | -11281.0% |
| Return on Invested Capital (ROIC %) | -25.2% | -35.1% | -5.6% |
| Cash & Short-Term Equivalents | $85.7M | $89.4M | — |
| Total Debt (Short + Long Term) | $28.1M | $40.8M | $1.33B |
| Total Stockholders' Equity | $715.2M | $517.8M | $2.73B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SYRE.